The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Consulting or Advisory Role - MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Sumitomo Group (Inst); Sumitomo Group (Inst); Sumitomo Group (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
Scoop: Multicenter phase I/II trial of BBI608 and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503).
 
Hiroki Hara
No Relationships to Disclose
 
Akihito Kawazoe
No Relationships to Disclose
 
Yasutoshi Kuboki
Honoraria - Bayer; Bayer; Bayer; Bayer; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Asahi Kasei; Asahi Kasei; Asahi Kasei; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Medical Review Co., Ltd.; Medical Review Co., Ltd.; Medical Review Co., Ltd.; Medical Review Co., Ltd.; Merck; Merck; Merck; Merck; Mitsubishi Tanabe Pharma; Mitsubishi Tanabe Pharma; Mitsubishi Tanabe Pharma; Mitsubishi Tanabe Pharma; Moroo Co.; Moroo Co.; Moroo Co.; Moroo Co.; Nipro Corporation; Nipro Corporation; Nipro Corporation; Nipro Corporation; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Otsuka; Otsuka; Otsuka; Otsuka; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Shiseido; Shiseido; Shiseido; Shiseido; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Research Funding - A2 Healthcare; A2 Healthcare; A2 Healthcare; A2 Healthcare; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Incyte; Incyte; Incyte; Incyte; IQvia; IQvia; IQvia; IQvia; Mediscience Planning; Mediscience Planning; Mediscience Planning; Mediscience Planning; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; NanoCarrier; NanoCarrier; NanoCarrier; NanoCarrier; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Parexel International Corporation.; Parexel International Corporation.; Parexel International Corporation.; Parexel International Corporation.; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Shionogi; Shionogi; Shionogi; Shionogi; Sumitomo Dainippon; Sumitomo Dainippon; Sumitomo Dainippon; Sumitomo Dainippon; Sysmex; Sysmex; Sysmex; Sysmex; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Nihonkayaku; Nihonkayaku; Nihonkayaku; Nihonkayaku; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Eiji Shinozaki
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Koji Takahashi
No Relationships to Disclose
 
Yuichi Mikamoto
No Relationships to Disclose
 
Nami Hirano
No Relationships to Disclose
 
Shogo Nomura
Employment - Asahi Kasei (I); Asahi Kasei (I); Asahi Kasei (I); Asahi Kasei (I)
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Pfizer; Pfizer; Pfizer; Pfizer; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Yosuke Togashi
No Relationships to Disclose
 
Hiroyoshi Nishikawa
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Celgene; Celgene; Celgene; Celgene; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Eisai; Eisai; Eisai; Eisai; MSD K.K; MSD K.K; MSD K.K; MSD K.K; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Research Funding - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BD Biosciences; BD Biosciences; BD Biosciences; BD Biosciences; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; KYOWA HAKKO BIO; KYOWA HAKKO BIO; KYOWA HAKKO BIO; KYOWA HAKKO BIO; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer; Sumitomo Group; Sumitomo Group; Sumitomo Group; Sumitomo Group; Sysmex; Sysmex; Sysmex; Sysmex; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Zenyaku Kogyo; Zenyaku Kogyo; Zenyaku Kogyo; Zenyaku Kogyo
 
Akihiro Sato
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma
Research Funding - Aspyerian Therapeutics (Inst); Aspyerian Therapeutics (Inst); Aspyerian Therapeutics (Inst); Aspyerian Therapeutics (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Oncolys BioPharma (Inst); Oncolys BioPharma (Inst); Oncolys BioPharma (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pentax Medical Devices; Pentax Medical Devices; Pentax Medical Devices; Pentax Medical Devices; Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Atsushi Ohtsu
Employment - Celgene (I); Celgene (I); Celgene (I); Celgene (I)
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Ono Yakuhin; Ono Yakuhin; Ono Yakuhin; Ono Yakuhin; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst)